第4巻 2008年10月　第4号

■臨床医のために

同時重複癌を合併した食道癌に対するDocetaxel/5-fluorouracil/Nedaplatinを用いた化学放射線療法
松谷　毅^1,2, 笹島　耕二^1,2, 鈴木　成治², 小林　由子³, 丸山　弘^1,2, 宮本　昌之^1,2, 横山　正^1,2, 松下　晃^1,2, 松田　明久^1,2, 田尻　孝^1
1日本医科大学大学院医学研究科臓器病態制御外科学
²日本医科大学多摩永山病院外科
³日本医科大学多摩永山病院放射線科

Chemoradiation Therapy with Docetaxel/Fluorouracil/Nedaplatin for the Patients with Esophageal Cancer and Simultaneous Double Primary Malignancy
Takeshi Matsutani^1,2, Koji Sasajima^1,2, Seiji Suzuki², Yuko Kobayashi³, Hiroshi Maruyama^1,2, Masayuki Miyamoto^1,2, Tadashi Yokoyama^1,2, Akira Matsushita^1,2, Akihisa Matsuda^1,2 and Takashi Tajiri^1
1Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School
²Department of Surgery, Nippon Medical School Tama Nagayama Hospital
³Department of Radiology, Nippon Medical School Tama Nagayama Hospital

To evaluate the efficacy and safety of chemoradiation therapy with docetaxel, fluorouracil, and nedaplatin for the patients with esophageal cancer and simultaneous double primary malignancy. Three patients with inoperable disease were enrolled to receive the combination of docetaxel 40 mg/m² (on days 1 and 21), nedaplatin 10 mg/body (on days 1∼5 and 21∼25), and fluorouracil 350 mg/m² (on days 1∼5 and 21∼25) with radiation (60 Gy in 2-Gy fractions over 6 weeks). Evaluated responses were a complete response in 1 patient and partial responses in 2 pateints. The overall response rate was 100%. Myelosuppressions with grade 2 leukopenia occurred in 2 patients (66%). This chemoradiation therapy is effective for and well-tolerable by patients with esophageal cancer and simultaneous double primary malignancy.

日医大医会誌 2008; 4(4), 197-200

Key words
double primary cancer, esophageal carcinoma, chemoradiation therapy

Correspondence to
Takeshi Matsutani, MD, Department of Surgery, Nippon Medical School Tama Nagayama Hospital, 1-7-1 Nagayama, Tama, Tokyo 206-8512, Japan
E-mail：matsutani@nms.ac.jp

受付：2008年7月31日　受理：2008年8月29日